New hope for rare lung cancer mutation? daratumumab shows promise in early trial

This study tested a drug called daratumumab in 8 people with a specific genetic mutation (STK11/LKB1) in advanced non-small cell lung cancer who had already tried other treatments. The goal was to see if the drug could shrink tumors. The study was small and designed to find early signals of effectiveness, with a target of at least 20% of patients responding.